Using Mounjaro for Weight Loss Without Diabetes: What You Need to Know

A patient walks into a primary care office having read about Zepbound but asks for Mounjaro. The clinician hesitates, then explains that the two drugs contain the same molecule — tirzepatide — at the same doses, manufactured by the same company, in pens that are nearly indistinguishable. The hesitation is not pharmacological. It is regulatory, and it shapes everything that happens next.

The Mounjaro-versus-Zepbound question is one of the more confusing situations in current obesity prescribing. The molecule is identical. The clinical effect is identical. The branding, the FDA indication, the insurance coverage, and the off-label/on-label distinction are entirely different. For patients trying to understand what their options actually are, the answer requires walking through how the same drug came to be sold under two names — and what that means for someone without diabetes who wants to use it for weight loss.

Same molecule, two brand names

Tirzepatide is a once-weekly injectable peptide developed by Eli Lilly. It is a dual agonist of the GLP-1 and GIP receptors — two gut hormone receptors involved in glucose regulation, satiety, and food reward processing. The drug was first approved by the FDA in May 2022 under the brand name Mounjaro for the treatment of type 2 diabetes, based on the SURPASS clinical trial program.

In November 2023, the same molecule received a second FDA approval for chronic weight management, under the brand name Zepbound, based on the SURMOUNT trials. Same active ingredient, same dosing range, same manufacturing process. Different indication, different label, different price.

This arrangement is not unusual in pharmacology. The same molecule frequently carries different brand names across indications — bupropion was sold as both Wellbutrin (depression) and Zyban (smoking cessation). What is unusual about tirzepatide is the magnitude of the off-label use that emerged between the diabetes approval and the obesity approval, when Mounjaro was the only available form of the molecule and clinicians were prescribing it off-label for weight loss in patients without diabetes.

Why two brand names matter clinically

Prescribing Zepbound for weight loss in a patient who meets the obesity indication is on-label. Prescribing Mounjaro for weight loss in a patient without diabetes is off-label. Off-label prescribing is legal and common — the FDA regulates marketing claims and indications, not clinical practice — but it has real consequences for insurance coverage, prior authorisation, and liability documentation.

What the evidence base actually shows

The SURMOUNT-1 trial, published in the New England Journal of Medicine in July 2022 with Ania Jastreboff of Yale as first author, established the efficacy of tirzepatide for weight loss in adults without diabetes. The trial randomised 2,539 patients with obesity to tirzepatide 5mg, 10mg, 15mg, or placebo for 72 weeks. Mean weight loss reached 20.9% on the highest dose, with 57% of patients achieving at least 20% body weight reduction.

This is the trial that supported the Zepbound approval. The molecule used in SURMOUNT-1 was identical to what is sold as Mounjaro. From a pharmacological standpoint, a patient receiving Mounjaro for off-label weight loss would be expected to experience the same outcomes documented in SURMOUNT-1, assuming dose equivalence.

The SURPASS program, which supported the original Mounjaro approval, tested tirzepatide in patients with type 2 diabetes and consistently showed weight loss as a secondary outcome alongside glycaemic improvement. SURPASS-2, published by Juan Frías and colleagues in 2021, demonstrated 11.2 kg weight loss on the 15mg dose in patients with diabetes — substantial, but lower than SURMOUNT-1's results because diabetes populations respond less robustly to weight loss interventions.

The off-label landscape: how it worked between approvals

Between May 2022 and November 2023, Mounjaro was the only commercially available form of tirzepatide. During this window, off-label prescription for weight loss in patients without diabetes became widespread. The clinical reasoning was straightforward: the SURMOUNT-1 results were available in preprint and publication from mid-2022, the molecule was approved and safe to prescribe, and there was no equivalent on-label option until Zepbound launched.

Most clinicians who prescribed Mounjaro off-label for weight loss did so within the same dosing ranges later approved for Zepbound. The clinical experience accumulated during this period informed the post-Zepbound prescribing environment, where the same patients often transitioned from Mounjaro to Zepbound when the obesity-indicated brand became available and insurance criteria allowed.

Where off-label Mounjaro prescribing still happens

The dominant scenarios in current practice: patients whose insurance covers Mounjaro for diabetes-adjacent conditions (prediabetes, metabolic syndrome) but does not cover Zepbound for obesity; supply shortages that affect one brand but not the other; and clinical relationships established during the off-label era that continued for continuity-of-care reasons.

The practice has shifted considerably since Zepbound became available. Major insurers and pharmacy benefit managers have tightened criteria specifically to prevent off-label Mounjaro prescribing for weight loss in non-diabetic patients, and many require formulary substitution to Zepbound or a documented medical reason for Mounjaro use.

Insurance coverage: where the brand split matters most

The clinically inconvenient reality is that insurance plans frequently cover one brand and not the other, despite the identical molecule. Diabetes coverage for Mounjaro is widespread because diabetes pharmacotherapy is well-established in formulary structures. Obesity coverage for Zepbound is far less consistent — many commercial plans exclude weight loss medications entirely, and those that do cover them often require BMI thresholds, documented prior weight loss attempts, and step-therapy through other agents first.

For patients without diabetes whose insurance does not cover Zepbound, the practical options narrow quickly. Lilly's direct-purchase program (LillyDirect) offers single-dose vials of Zepbound at reduced cash prices. Manufacturer savings programs can lower out-of-pocket costs for patients with commercial insurance but not government-funded plans. Compounded tirzepatide entered the market during shortages but has become legally restricted as the shortage status has resolved.

The compounded tirzepatide question

During the FDA-declared shortage of tirzepatide in 2023 and 2024, compounding pharmacies were legally permitted to produce compounded versions of the molecule. Many patients without diabetes accessed tirzepatide this way at substantially lower prices than the branded Mounjaro or Zepbound. The FDA resolved the shortage status for tirzepatide in late 2024, after which large-scale compounding became legally restricted to specific patient-specific circumstances rather than general supply.

The clinical implications are mixed. Compounded tirzepatide is not subject to the same manufacturing oversight as the branded products, and the FDA has issued warnings about adverse events traced to compounded preparations. Some patients on compounded tirzepatide have transitioned to LillyDirect vials at comparable cash prices once available. The legal and clinical landscape continues to shift, and patients considering compounded options should verify current regulatory status with their prescriber.

Clinical considerations specific to non-diabetic use

The pharmacological profile of tirzepatide is the same regardless of indication, but the clinical context shapes monitoring. In patients without diabetes, baseline glucose is normal, and the drug's glucose-lowering effects are modest enough that clinically significant hypoglycaemia is uncommon — typically only when other glucose-lowering medications are also present.

The dose-escalation protocol is identical: 2.5mg weekly for four weeks, then 5mg, with subsequent escalations at four-week intervals as tolerated, up to a maximum of 15mg. Gastrointestinal side effects — nausea, diarrhoea, constipation — follow the same pattern documented in both SURPASS and SURMOUNT trials, with most clustering during titration.

The medullary thyroid cancer boxed warning applies equally to Mounjaro and Zepbound, based on rodent studies that have not been replicated in human surveillance to date. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 remains a contraindication for both brands.

What about prediabetes?

Patients with prediabetes — typically defined as HbA1c between 5.7% and 6.4%, or fasting glucose 100–125 mg/dL — occupy a middle position. They do not meet the diabetes threshold that would justify Mounjaro on-label, but the metabolic dysfunction is clinically meaningful and often coexists with obesity. In practice, prediabetes plus obesity usually points toward Zepbound rather than Mounjaro, with the prediabetes serving as a comorbidity that strengthens the case for treatment under the obesity indication. Some insurance plans treat prediabetes as a qualifying comorbidity that reduces the BMI threshold from 30 to 27.

Practical guidance for patients without diabetes

If you do not have diabetes and are considering tirzepatide for weight loss, Zepbound is the on-label and clinically appropriate choice in most cases. Prescribing logic, insurance pathways, and pharmacist dispensing all align around the obesity-indicated brand. Asking for Mounjaro when Zepbound is appropriate often complicates rather than simplifies access.

If Zepbound coverage is denied, the productive next steps usually include: appealing the denial with documentation, exploring LillyDirect's cash-pay options for vials, and reviewing whether you meet criteria for any diabetes-adjacent indication that might support coverage. Our guide to getting GLP-1 medications covered and prior authorisation strategies covers the procedural detail.

For the broader trial context behind Zepbound, see our breakdown of the SURMOUNT program results. For comparison with the other major GLP-1 option, see tirzepatide versus semaglutide.

Key takeaways

• Mounjaro and Zepbound contain the same molecule (tirzepatide) at the same doses; the brands differ only in FDA indication — diabetes versus obesity.
• SURMOUNT-1 (Jastreboff, NEJM 2022) established 20.9% mean weight loss in non-diabetic obesity, supporting the Zepbound approval; the molecule used was identical to what is sold as Mounjaro.
• Off-label Mounjaro prescribing for weight loss in non-diabetic patients was widespread between May 2022 and November 2023, before Zepbound was available, and has narrowed considerably since.
• Insurance coverage frequently splits across the two brands despite the identical molecule, with diabetes coverage for Mounjaro more common than obesity coverage for Zepbound.
• For non-diabetic patients in 2026, Zepbound is the on-label option; if coverage is denied, LillyDirect cash-pay vials and appeal strategies are the practical next steps.